Pharma Focus Asia
KP - Sustainable Packaging Solutions

Lonza Announces to Expand HPAPI Development and Manufacturing Capacity


Lonza announced an expansion of Highly Potent API (HPAPI) capabilities from development to commercial scale manufacturing, including formulation and delivery.


Lonza has industry-leading capability in HPAPI development and manufacturing complemented with particle engineering and specialised finished drug products for oral and parental delivery applications.

The new expansion will add two 4m3-scale, multi-purpose production lines for HPAPI manufacturing, improving Lonza's flexibility in existing production lines, helping in shorter time-to-market and accelerated approval timelines for partners.

Lonza reports that the facility will support the delivery of products from AstraZeneca portfolio under a long-term manufacturing agreement.

The HPAPI capacity expansion is expected to be operational by July 2020.


NameLonza Pharma & Biotech
ScheduleScheduled to be operational by 2020
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?